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Clinical Relevance: Changes in the GCF biotype during the transition from gingivitis to periodontitis 
are of diagnostic interest. As human studies are precluded due to the length of study this work offers 
a unique opportunity to shed light on proteomic changes during periodontitis and identify diagnostic 
biomarkers. 
Principal Findings: Using state-of-the-art mass spectrometry we were able to identify significant 
increases in 40 proteins by mass spectrometry between mild periodontitis and gingivitis, and 
confirmed one protein by ELISA.  
Practical Implications: The work shows that this approach is viable for the identification of 
biomarkers of periodontitis in GCF that change significantly during the transition from gingivitis to 
periodontitis in dogs. Further studies involving greater GCF volumes may help validate more 
biomarkers.. 
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Abstract 
Aim: Inflammatory periodontal disease is widespread in dogs. This study evaluated site-specific 
changes in the canine gingival crevicular fluid (GCF) proteome during longitudinal progression from 
very mild gingivitis to mild periodontitis. Periodontitis diagnosis in dogs requires general anaesthesia 
with associated risks and costs; our ultimate aim was to develop a periodontitis diagnostic for 
application in conscious dogs. The objective of this work was to identify potential biomarkers of 
periodontal disease progression in dogs.  
 
Materials and methods: GCF was sampled from a total of ten teeth in eight dogs at three different 
stages of health/disease and samples prepared for quantitative mass spectrometry (data available 
via ProteomeXchange; identifier PXD003337). A univariate mixed model analysis determined 
significantly altered proteins between health states and six were evaluated by ELISA.  
 
Results: 406 proteins were identified with 84 present in all samples. The prevalence of 40 proteins 
was found to be significantly changed in periodontitis relative to gingivitis. ELISA measurements 
confirmed that haptoglobin was significantly increased.  
 
Conclusions: This study demonstrates for the first time that proteins detected by mass spectrometry 
have potential to identify novel biomarkers for canine periodontal disease. Further work is required 
to validate additional biomarkers for a periodontitis diagnostic.   
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Introduction  
Periodontitis is the most widespread oral disease in dogs; depending on the population studied 
between 44% and 64% of dogs are affected (Butkovic et al., 2001; Kyllar et al., 2005; Kortegaard et 
al., 2008; Hamp et al., 1984).  Variations in prevalence estimates are likely due to the different age 
and breed compositions of the study groups and the diagnostic criteria employed to define 
periodontitis.  In humans the prevalence is estimated at 47% in adults over 30 years and over 70% in 
adults older than 65years (Eke et al 2012), highlighting the variation with age in a divergent 
mammal.  
It is widely accepted that dysbiosis within the human dental plaque biofilm is the primary initiator of 
periodontitis (Roberts & Darveau 2015); though how these organisms trigger disease and the basis 
for the subsequent pathological events thereafter appears to be host-mediated (Bartold & VanDyke 
2013). One working hypothesis is that specific antigens or enzymes produced by bacteria within the 
plaque biofilm initiate the activation of the host inflammatory response, which fails to resolve and 
becomes chronic and destructive in nature (VanDyke 2009). The dog oral microbiome was recently 
investigated by Dewhirst et al (2012). The study demonstrated that these divergent mammalian 
species (dog versus human) only share 16.4% of oral taxa when the accepted 98.5% 16S rRNA 
sequence similarity cut off was employed. However, studies over the last 40 years have 
demonstrated that plaque is also the initiating factor of periodontal inflammation in dogs (Egelberg 
1965; Lindhe et al 1975). From a 16S rRNA pyrosequencing study of plaque in a cross-sectional 
cohort study of dogs we identified a number of bacterial species whose prevalence was associated 
with either health or early periodontitis (Davis et al 2013). More recently we followed 52 miniature 
schnauzers, a small-sized breed at risk of developing periodontitis, for 60 weeks (Marshall et al 2014) 
without any tooth cleaning regimes. Thirty five of these animals had 12 or more teeth develop 
periodontitis during the course of the study and the incisors were the most likely to develop disease 
on the lingual aspect. Older dogs developed periodontitis more rapidly than younger dogs. This 
study illustrated the speed with which periodontitis can develop in a small breed of dog in the 
absence of any oral hygiene regime.  
In both humans and dogs the initial stages of periodontal disease are observed clinically as red and 
inflamed gingivae, defined as “gingivitis”.  Without treatment to remove and disrupt the plaque 
biofilm, gingivitis may progress to periodontitis. In dogs a periodontal scoring system based on levels 
of inflammation and probing periodontal pocket depths has been developed for diagnosis (Wiggs & 
Lopbrise, 1997). In this system periodontitis (PD) scoring is staged as absolute health (G0), through 
four levels of gingivitis increasing by severity (G1-G4) followed by four PD levels (PD1-PD4) with PD4 
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being the most severe and PD1 being very early periodontitis. To accurately assess the periodontal 
health of a dog, specialist veterinary dental expertise, periodontal probing pocket depths and 
radiological confirmation under general anaesthesia are required. As this expertise is not always 
available in an average clinical setting and to reduce the anaesthetic burden of pets the current 
program of work set out to identify protein biomarkers for periodontitis in dogs. The ultimate aim 
being to develop a diagnostic tool that may be used to screen GCF or saliva taken from conscious 
dogs. A mass spectrometry based proteomics approach was applied to a naturally occurring 
longitudinal periodontitis sample set.. The sample archive studied was unique in that it was collected 
from a longitudinal study of disease progression. The samples were selected from 52 miniature 
schnauzers as they progressed from health to mild periodontitis over a 60-week period prior to 
scaling and prophylaxis to arrest disease progression and re-establish health (Marshall et al., 2014). 
 
For the non-presumptive analysis of proteins detected in oral fluids, mass spectrometry based 
proteomics is acknowledged as the best tool available; hence it was selected for this study (Grant 
2012). The technology confers the ability to examine the complex composition of oral fluids, such as 
gingival crevicular fluid (GCF) and saliva which can facilitate the identification of biomarkers of 
health and disease. Advances in recent years mean that proteins can be compared quantitatively 
across samples by the addition of isobaric mass tags (e.g. ITRAQ or TMT labels) (Grant et al 2010) or 
by label free quantitation (Bostanci et al 2010 & 2013) in these fluids.  So far  human studies of 
experimental gingivitis (Grant et al 2010 and Bostanci et al 2013) or of periodontitis (Bostanci et al 
2010; Trinidade et al 2015) have yielded large number of proteins, allowing for an in-depth insight 
into inflammatory diseases of the gingivae. However to date it has not been possible to follow 
human participants during the progression from health to gingivitis and subsequently to 
periodontitis in the same individuals. The challenges to complete such an investigation include 
extended timescales, the significant resource to screen volunteers regularly enough to meet ethical 
considerations and the subsequent impact on volunteer retention and expense.  
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Methods 
Longitudinal Trial Design and Scoring Criteria 
In a previous longitudinal study individual teeth were tracked in 52 dogs (equating to 2155 teeth) 
with dental assessments under general anaesthesia at 6 weekly periods up to 60 weeks. The disease 
stage of each tooth was assessed using the Wiggs & Lopbrise PD scoring system described in full by 
Marshall et al (Wiggs & Lopbrise, 1997; Marshall et al., 2014) and shown for the stages used in the 
present study in table 1. Probing pocket depth was measured from the gingival margin to the 
bottom of the periodontal pocket. Gingival recession was measured from the cementoenamel 
junction (CEJ) to the gingival margin. Total attachment loss was calculated as the sum of the gingival 
recession and the periodontal probing pocket depth in accordance with established protocols 
(Harvey 2005). Samples of gingival crevicular fluid and subgingival plaque were taken and archived at 
each time point (Marshall et al., 2014).  In this way very mild gingivitis (G1) and moderate gingivitis 
(G3) samples were collected from all teeth that eventually progressed to mild periodontitis (PD1). A 
subset of these samples from 10 teeth in 8 dogs was used in the present study. The mean age of the 
dogs sampled was 3.2 years (SE + 0.5) and genders were equally balanced (Table 2). The study was 
approved by the WALTHAM® Animal Welfare and Ethical Review Body and run under licensed 
authority in accordance with the UK Animals (Scientific Procedures) Act 1986. At the end of the 
study all dogs had prophylactic treatment including a scale and polish and tooth brushing to re-
establish healthy gingiva.  
All teeth were scored individually based upon a modified Wiggs & Lobprise scoring system described 
in full by Marshall et al. (2014). In short: a gingivitis score between 0 and 4 was recorded for the 
mesial, mid-buccal, distal and palatal/lingual aspect of each tooth using a modified combination of 
the gingival index (GI) and sulcus bleeding index (SBI). Periodontitis stage 1 (PD1) was classified as 
being up to 25% attachment loss. Probing depths were measured from the gingival margin to the 
base of the periodontal pocket.  
 
Collection and Preparation of Clinical Samples 
Gingival crevicular fluid (GCF) samples were collected on paper points for 30 seconds and stored at -
80 °C. Samples included in the study were selected in order to represent a variety of tooth types 
from a number of different dogs as the teeth progressed from very mild (G1) to moderate (G3) 
gingivitis through to mild periodontitis (PD1). A total of ten teeth at three time points (representing 
each health state) from a total of eight miniature schnauzers (30 samples in total) were chosen 
(Table 2). Proteins were extracted from the paper points by wetting with ammonium bicarbonate 
buffer (100 mM, 400 µl), vortexing for 30 s and the solution was then placed into a clean snap top 
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Eppendorf tube. Further ammonium bicarbonate (100 mM, 200 µl) was added to the GCF containing 
paper points to remove any retained proteins, vortexed for 30 s, centrifuged at 13,000 r min-1 for 5 
min, and added into the initial extraction solution resulting in a single fluid containing tube (600 µl). 
Dithiothrietol (50 mM, 20 µl) was added to the samples and incubated at 60 °C for 45 min. The 
samples were returned to room temperature, prior to addition of iodoacetamide (22 mM, 100 µl) 
and incubated at room temperature in the dark for 25 min. A further small volume of dithiothrietol 
(50 mM, 2.8 µl) was added to quench any unreacted iodoacetamide. Trypsin (0.4 µg) was added to 
each sample and incubated overnight at 37 °C. The samples were vacuum centrifuged dry, 
resuspended in trifluoroacetic acid (TFA) (200 µl, 0.5 % v/v), de-salted using a C18 MacroTrap 
(Michrom, Auburn, CA, USA) and again vacuum centrifuged dry. 
 
For comparison a small equivalent fraction from all GCF samples was pooled (master sample mix) 
and labelled with an iTRAQ mass tag of 117. Very mild gingivitis (G1), moderate gingivitis (G3) and 
mild periodontitis (PD1) samples were labelled with iTRAQ (4plex, AB SCIEX) labels 114, 115 and 116, 
respectively. All samples were incubated with the labels for two hours before being pooled into 
individual tooth samples. 
 
The ten combined samples (containing 3 samples per tooth, one at each stage of health or disease) 
were vacuum centrifuged dry and resuspended in mobile phase A (10 mM KH2PO4, 20 % (v/v) 
acetonitrile, pH 3, 100 µl) for strong cation exchange (SCX) liquid chromatography. The peptides 
were separated on a polysulfethyl A column (100 mm × 2.1 mm, 5 µm particle size, 200 Å pore size; 
PolyLC, Columbia, MD, USA) with a javelin guard cartridge (10 mm × 2.1 mm, 5 µm particle size, 200 
Å pore size; PolyLC) using mobile phase A and mobile phase B (10 mM KH2PO4, 500 mM KCl, 20 % 
(v/v) acetonitrile, pH 3). The separation gradient ran 0 to 80% mobile phase B over 90 min, resulting 
in 17 × 750 µl fractions. Fractions 1-4, 5-7, 8-10, and 11-17 were combined to provide four fractions. 
Each fraction was vacuum centrifuged to ~50 µl and desalted using C18 ZipTips (Millipore). The 
desalted peptides were vacuum centrifuged dry and resuspended in formic acid (20 µl, 0.1 (v/v)). 
 
Mass Spectrometry  
Online LC-MS/MS was performed on a Dionex UltiMate 3000 RLSCnano (Thermo Fisher Scientific, 
Bremen, Germany) system coupled to an LTQ-Orbitrap Velos ETD (Thermo Fisher Scientific). Peptides 
were loaded onto a 150 mm Acclaim PepMap100 C18 column (LC Packings, Sunnyvale, CA, USA) in 
formic acid (0.1 % (v/v)), and separated over a 90 min linear gradient from 3.2 % to 44 % mobile 
phase B (acetonitrile with formic acid (0.1 % (v/v)) with a flow rate of 350 nl min-1. The column was 
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then washed with 90 % mobile phase B before re-equilibrating at 3.2 % mobile phase B. The column 
was maintained at 35 °C. The LC system was coupled to an Advion Biosciences TriVersa NanoMate 
source (Ithaca, NY, USA) which infused the peptides with a spray voltage of 1.7 kV. Peptides were 
infused directly into the mass spectrometer. The mass spectrometer performed a full FT-MS scan 
(m/z 380-1,600) and subsequent collision induced dissociation (CID, 35% normalized collision energy 
NCE) MS/MS scans of the three most abundant ions followed by higher energy collisional 
dissociation (HCD 55 NCE) of the same three ions. Analysed ions were placed on an exclusion list for 
60 s. The CID and HCD spectra were used for peptide identification and quantification, respectively. 
Each SCX set (i.e. the four SCX fractions from each sample) was run in sequence followed by a blank 
and repeated in triplicate. 
 
Mass Spectrometry Data Processing and Annotation 
The data were analysed using Proteome Discoverer (version 1.4, Thermo Scientific). Data from each 
SCX set were analysed together and each replicate searched independently. Mascot and SEQUEST 
algorithms were used to search the data with identical settings used. The database was the UniProt 
Canis lupus familiarus (29,293 entrants downloaded 02/2014). The data were searched with the 
following settings: trypsin as the enzyme with a maximum of two missed cleavages, 10 ppm mass 
accuracy for the precursor ion, fragment ion mass tolerance was set at 0.8 Da, 
carbamidomethylation of cysteine and iTRAQ addition to the N-terminus and lysine residues were 
set as fixed modifications, and phosphorylation of serine, threonine and tyrosine was set as a 
variable modification as was oxidation of methionine and iTRAQ addition to tyrosine. The search 
results from each of the technical replicates were combined and proteins which were identified with 
two or more unique peptides were classed as identified. Only unique peptides were used for protein 
quantification (performed in Proteome Discoverer) and protein grouping was employed (only 
proteins which contained unique peptides were used). The mass spectrometry proteomics data have 
been deposited to the ProteomeXchange Consortium (Vizcaíno et al 2014) via the PRIDE partner repository 
with the dataset identifier PXD003337.  
 
 
ELISA Methodology 
In an attempt to corroborate the Mass spectrometry findings, samples were screened on canine 
specific assays for Pyruvate kinase (TSZELISA,USA; limit of detection 1.56ng/ml), Haptoglobin (Life 
Diagnostics Incorporated, USA; limit of detection 1.95ng/ml), Calcium binding protein S100A8 
(NeoBioLab, USA; limit of detection 156.25pg/ml), Myosin 9 (Wuhan EIAab Science Co. Ltd, China; 
limit of detection 31.2pg/ml), Type 1 dog keratin cytoskeletal 10 (Wuhan EIAab Science Co. Ltd, 
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China; limit of detection 0.31ng/ml) and Canine anti-immunoglobulin binding protein 
(MyBioSource,USA; limit of detection 0.3125g/ml).  
 
Due to the limited amount of protein in each GCF sample it was not possible to screen each tooth 
sample against the six different ELISAs; hence a G1 and PD1 sample from the same tooth was 
screened with a single ELISA. Samples from ten dogs were screened on each ELISA (see 
supplementary data table 2 for the 60 teeth screened). The samples were selected from the 
biobanked samples from the wider study (Marshall et al 2014) from teeth with the most similar 
characteristics in terms of progression from G1 to PD1 and location to those used in the proteomics 
discovery experiments. GCF paper point samples were suspended in sterile phosphate buffered 
saline (PBS) with volumes varying dependent on the manufacturer’s instructions, typically between 
110 and 210µl. The sample was thoroughly mixed and centrifuged, paper points were then trapped 
in the lid of the tubes and centrifuged again for complete elution. The eluted sample was assayed in 
duplicate immediately according to the manufacturer’s instructions. The assays were quantitative 
solid phase sandwich enzyme linked immunoassays with the exception of the Calcium binding 
protein S100A8 and Type 1 dog keratin cytoskeletal 10 which were competitive binding 
immunoassays. 
 
Statistical Analysis 
An analysis was performed to determine which mass spectrometry proteins were observed in 
samples at significantly different levels between health states. To prioritise proteins that would be 
relevant as biomarkers only proteins identified in at least one replicate in all 10 teeth, regardless of 
health state, were included in this analysis. The loge transformed abundance of each protein was 
analysed univariately using mixed effects methodology with health state as the fixed effect and 
health state nested in tooth as the random structure. For each protein, abundances for each health 
state and fold changes between health states were estimated with 95% confidence intervals. Due to 
the increased risk of false positives with the analysis of many proteins, p-values were adjusted using 
the Benjamini-Hochberg false discovery rate method (Benjamini & Hochberg, 1995). Putative 
functions were curated from the Uniprot entry for each protein. 
 
For statistical analysis of the ELISA data, the loge transformed protein concentration was analysed 
using a mixed effects model with health state as the fixed effect and tooth as the random effect. The 
concentration for each health state and fold changes between health states were estimated with 
95% confidence intervals.  
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All statistical analyses were performed in R version 3.2.0 (2015-04-16), The R Foundation for 
Statistical Computing (www.r-project.org). Packages used were lme4 (Bates et al 2014) and 
multcomp (Hothorn et al 2008).   
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Results 
Proteomic analysis of GCF samples 
GCF samples collected from ten teeth at three time points from a total of eight miniature schnauzers 
(30 samples in total) were included in the study. The samples represented periodontal disease 
progression from very mild (G1) to moderate (G3) gingivitis through to mild periodontitis (PD1). 
Table 2 illustrates the time taken for the development to each stage for each tooth. The mean (+/- 
SE) for progression between states was:  G1 to G3 15.6 (+ 2.4) weeks; G3 to PD1 14.4 (+ 2.8) weeks; 
and G1 to PD1 30.0 (+ 4.1) weeks. 
 
Cumulatively, a total of 406 canine proteins were identified and quantified, after passing the 1% 
peptide false discovery rate, in at least one LC-MS/MS run. Variations between teeth in the 
prevalence of these proteins at each disease state are shown in figure 1. This hive panel 
demonstrates the intra-individual variation between samples, depicting both changes per tooth type 
and within an individual subject. Neither the rate of progression nor the putative size of the tooth 
appeared to be correlated with the quantity of proteins at each stage when examining individual 
teeth. Indeed where the same dog developed inflammation in two teeth across the course of the 
study the two teeth showed remarkably individual responses.  
 
Of the 406 proteins, 84 (20.7%) were identified in at least one triplicate run for all ten GCF samples 
(Supplemental Table 1). The quantified values of the 84 proteins found in all samples are 
represented in Figures 2 showing the variation in protein intensity between very mild gingivitis, 
moderate gingivitis, and periodontitis. Figure 3 shows the fold changes in proteins between 
moderate gingivitis: very mild gingivitis (G3/G1), mild periodontitis: very mild gingivitis (PD1/G1) and 
mild periodontitis: moderate gingivitis (PD1/G3). It is interesting to note that there appears to be a 
much greater increase in total protein amount in mild periodontitis in comparison to both stages of 
gingivitis (figure 2); whereas both moderate gingivitis vs very mild gingivitis and mild periodontitis vs 
very mild gingivitis have large variations (figure 3). This could be explained if greater GCF volumes 
were obtained from periodontitis sites than healthy or gingivitis sites; however a limitation of the 
present study was that we did not measure GCF volumes obtained.  As a consequence of the greater 
increase in protein in mild periodontitis separation between disease, i.e. mild periodontitis or 
moderate gingivitis, and very mild gingivitis is easily identified, whereas identification between mild 
periodontitis and moderate gingivitis is far more difficult. 
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To investigate which proteins changed significantly between disease states, a univariate mixed 
model analysis of these proteins was employed.  Eighty-four proteins were identified as being 
present in at least one replicate in all 10 teeth, resulting in 252 comparisons between the three 
health states. Of these, 58 contrasts from 40 different proteins were significant after Benjamini-
Hochberg correction (Table 3). These significant differences in protein prevalence were either 
between very mild gingivitis (G1) and PD1 or moderate gingivitis (G3) and PD1. No significant 
differences were observed in protein prevalence between very mild and moderate gingivitis. All 
proteins with significant changes increased in prevalence through the disease process with the 
greatest fold changes observed in haptoglobin, S100A8, haemoglobin subunit beta, S100A12, 
Fibrinogen beta chain and 14-3-3 protein beta/alpha. Eight of the significant proteins were 
uncharacterised; the remaining proteins could be grouped by function as relevant to immunity and 
inflammation, blood constituents, structural, metabolic, housekeeping and biosynthetic by gene 
ontology analysis.  
  
ELISA verification of proteomic analysis 
Of the six proteins screened by ELISA, only haptoglobin was detected in all GCF samples tested. A 
significant difference in haptoglobin concentration was observed between the health states 
(p=0.0001) with a 2.17 fold change between PD1/G1 (95% CI = 1.46, 3.22) by ELISA compared to the 
estimated 2.48 fold change (95% CI = 1.32, 4.66) 
from the mass spectrometry results (figure 4 & table 3). PBS adversely altered the sensitivity of both 
S100A8 and immunoglobulin binding protein assays and detection for these proteins in GCF samples 
was not conclusive. Myosin 9 and Keratin type 1 cytoskeletal 10 proteins could be detected at low 
levels in some GCF samples but several samples were below the limit of detection (supplementary 
data table 2) limiting conclusions to be drawn.  Pyruvate Kinase could not be detected in any 
samples. 
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Discussion 
The present study has investigated for the first time site specific longitudinal changes in the GCF 
proteome quantitatively from miniature Schnauzers that naturally develop periodontitis. With our 
experimental design we were able to follow eight individuals and ten teeth across the course of the 
60 week study. This yielded data not only on inter-individual variation but also on intra-individual 
variation. Although this  inter-individual variation was quite high it was possible to gain information 
on 84 proteins that were found in all samples. This was approximately 21% of the total proteins 
detected. The method employed, fragmentation and quantitation of the top three peptides in each 
duty cycle, will have significantly contributed to the variation observed. Other techniques such as 
MSE (Levin et al 2011) and SWATH methods (Sajic et al 2015) could be employed in the future to gain 
more information with less missing data. Previously we have used pooled samples (Grant et al 2010), 
which will aid in more consistent protein identification but loses information on individual variation.  
 
In this study we searched the mass spectrometry data against the open access reference dog 
database in Uniprot. However, by using an in-house database of microbial species detected by 
Dewhirst et al (2012) it was also possible to search against a combined database containing bacterial 
genome sequences from dog oral microbiota and dog proteomes. Although we are not presenting 
these data here, as the canine oral microbiota genome database has not been published, we only 
detected 28% bacterial proteins in the total number of proteins found. None of these bacterial 
proteins were detected in samples from all teeth.  This is in agreement with other studies (Grant et 
al 2010, Bostanci et al 2010) as this type of metaproteomics is acknowledged to be associated with a 
number of problems. Indeed Kuboniwa et al (2012) highlighted that any system in which hundreds of 
individual species are present, such as in oral plaque, the proteins detected by proteomics will be 
dominated by a small number of peptides that are amenable to the approach used and that as the 
community complexity increases this effect becomes more pronounced. In communities with several 
highly related species, such as the Streptococci, it also becomes difficult to assign peptides to one 
species as the proteins may be highly homologous in sequence identity (Muth et al 2015). 
Additionally, traditional false discovery rate calculations breakdown, causing very conservative 
identifications of a few proteins or a larger number of identifications with less precision in 
identification (Muth et al 2015). 
Through univariate analysis, 40 proteins were identified to be significantly increased  between mild 
periodontitis and  moderate gingivitis or mild periodontitis and very mild gingivitis. That no proteins 
were observed to increase significantly between very mild to moderate gingivitis may be due the 
size of the sample set limiting statistical power.  The 40 significant proteins can be grouped 
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according to their function with structural proteins being most represented followed by those 
involved in immunity and inflammation. Within the structural group, keratins (5/11) make up nearly 
half of the proteins identified and they displayed very similar changes in profile across the study. 
Keratins indicative of both stratified and simple epithelia were found suggesting that there is 
destruction of both the sulcular and junctional epithelia occurring. Lymphocyte cytosolic protein 1 
(LCP-1 or Plastin-2) is also classed as a structural protein and has been found in a number of 
proteomic studies examining GCF and saliva (Grant et al 2010, Bostanci et al 2010, Bostanci et al 
2013). Öztürk et al (2014) have shown that it is a potential biomarker for periodontal diseases in 
humans. Additionally, there are a number of other proteins that are of likely neutrophilic in origin: 
the S100 proteins A8, 9 and 12, myeloperoxidase, neutrophil elastase and lysozyme. Neutrophils are 
the most abundant cells in the circulation and are found abundantly in human periodontal lesions 
(Scott & Krauss 2012). They are the first responding cells to infection and injury utilizing their protein 
and chemical arsenal to counteract the insult. For example, myeloperoxidase will produce 
hypochlorous acid, a strong bactericidal agent, and trigger for neutrophil extracellular trap release 
(Palmer et al 2012) and neutrophil elastase will degrade the extracellular matrix to allow neutrophil 
access to the site of action. The S100 proteins are a family of calcium binding proteins with multiple 
functions (Gross et al 2014). All three found here are abundant in neutrophils and S100A8 and 
S100A12 are known to be chemoattractive to neutrophils and will amplify neutrophil recruitment. 
S100A8 can be oxidised by reactive oxygen species produced by neutrophils and is rendered no 
longer a chemoattractant (Goyette & Geczy 2011). S100A12 however will still maintain the 
recruitment of neutrophils as it does not contain any oxidatively modifiable cysteine residues 
(Goyette & Geczy 2011). The presence of neutrophils will increase the amount of oxidative stress 
due to the production of reactive oxygen species. It is interesting to see the significant increase in 
two antioxidant response proteins, namely NQO1 and thioredoxin, across the course of the study. 
The redox balance between antioxidants and oxidants is important for prevention of bystander 
tissue damage (Chapple & Matthews 2007).  
 
HSPA5 was found to be significantly increased in mild periodontitis compared to very mild gingivitis. 
One of the key functions of this protein in humans is in the unfolded protein response and 
endoplasmic reticulum (ER) stress (Baird et al 2013). Kebschull et al (2014) reported in a 
transcriptomic analysis of human gingival biopsies that ER stress related pathways were increased in 
periodontitis. Indeed, Baird et al (2013) demonstrated increases in HSPA5 in ex vivo cultured gastric 
cells infected with Helicobacter pylori.  There is an acknowledged cross over in signalling pathways 
   15 
between the innate immune and ER stress response pathways (Claudio et al 2013) and although this 
is just one protein, it may be an insight into how human and dog periodontal diseases overlap. 
 
Overall the proteins found depict an inflammatory response with associated tissue destruction from 
neutrophils and the epithelium. These two cell types will be the most abundant adjacent to the GCF 
collection site and thus could be expected to contribute the most. This study used a top 3 technique 
for identification of peptides in the mass spectrometer. Greater depth and improved consistency, as 
mentioned above, may yield deeper insights and proteins from different origins. Complementary 
techniques such as multiplexed analysis of low abundance cytokines and chemokines could improve 
our understanding of the periodontal process in dogs. The results of the haptoglobin ELISA screen 
are proof of principle that the iTRAQ approach to discover biomarkers is sound. However the fact 
that only one in six of the canine ELISA kits were successful in quantifying protein in GCF samples 
presents a significant hurdle in validating these putative biomarkers. Whilst all of the ELISAs claim to 
be dog specific the main challenge appears to be one of sensitivity with the detectable concentration 
of target proteins in the GCF samples being so low. It is not clear if this is an issue with the 
specificity/ sensitivity of the ELISAs, relatively low levels of the proteins in GCF, degradation of the 
proteins whilst in storage or a combination of these. This challenge will need to be addressed if a 
canine GCF based periodontal disease diagnostic is to be developed. Further mass spectral 
techniques, which are independent of antibody specificities, such as selected or multiple reaction 
monitoring (SRM or MRM) are promising candidates (Harlan & Zhang 2014).  Further verification or 
production of ELISAs aimed at detecting dog proteins is another, though, longterm option. For 
instance production of recombinant dog proteins to verify antibody specificity and analysis of post 
translational modifications may be important in this context. This is particularly relevant as a small 
panel of biomarkers will most likely the best way forward for robust detection of periodontal 
disease. Additionally, here we used GCF samples, rather saliva. As GCF requires technical expertise 
to collect it will also be important to validate biomarkers in saliva in the future.  
 
A great advantage of our study is the possibility of examining the progression of very mild gingivitis 
to mild periodontitis. The current consensus statement views gingivitis and periodontitis as a 
continuum of chronic inflammatory disease (Tonetti et al 2015) in humans. However it is extremely 
difficult to assess the natural directional progression from gingivitis to periodontitis in humans. 
Therefore, our study represents a unique opportunity to examine natural progression in a canine 
model. The insights gained here not only could give rise to a tool to assist veterinarians but can also 
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shed light on progression of a disease common in the animal kingdom (Oz & Puleo et al 2011; Ismaiel 
et al 1989).  
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Figure legends 
Figure 1. Hive panel showing individual hive plots to compare protein levels between very mild 
gingivitis (G1), moderate gingivitis (G3) and mild periodontitis (PD1) across individuals. All axis show 
the same magnitude (arbitrary units). Colours denote tooth type (maxilla or mandible): Pink 
represents tooth 3 incisor; Purple represents tooth 4 canine; Green represents tooth 7 premolar; 
Turquoise represents tooth 8 premolar; Orange represents tooth 9 molar. The yellow and red boxes 
highlight samples taken from different teeth but in the same individual animal. Dog ID is shown 
above or below each plot for reference.  
 
Figure 2. Hive plots comparing average protein levels in all samples between very mild gingivitis (G1), 
moderate gingivitis (G3) and mild periodontitis (PD1). i. All proteins identified across the experiment, 
including proteins only identified in one tooth. ii. Proteins identified in all ten teeth; the magnitude 
of the protein levels found is smaller than for all the proteins and so an enlargement of the core 
proteins identified in all teeth is also provided. 
 
Figure 3. Hive plots showing ratios of average protein levels between health states in all samples: 
moderate gingivitis:very mild gingivitis (G3/G1), mild periodontitis:very mild gingivitis (PD1/G1), and 
mild periodontitis:moderate gingivitis (PD1/G3). i. All proteins identified across the experiment, 
including proteins only identified in one tooth. ii. Proteins identified in all ten teeth; the magnitude 
of the fold changes found is smaller than for all the proteins and so an enlargement of the core 
proteins identified in all teeth is also provided. 
 
Figure 4. Comparison of Haptoglobin quantities determined by ELISA (on left) and mass 
spectrometry (on right). Data displayed mean +/-SE.  
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Table 1. Disease scoring system adapted from Marshall et al 2014 to show the stages used in this 
study. G1: very mild gingivitis; G3: moderate gingivitis; PD1 mild periodontitis 
 
  
Score Gingivitis Periodontal 
probing depth 
(mm) 
 
Gingival 
recession 
(mm) 
 
G1 
 
Very mild gingivitis 
(red, swollen but no 
bleeding on 
probing) 
 
≥1 to 2 0 
G3 
 
Moderate gingivitis 
(red, swollen and 
immediate 
bleeding on 
probing) 
 
≥1 to 2 0 
PD1 
 
Gingivitis must be 
present (i.e. active 
periodontitis) 
 
>2 (>3 on 
canine teeth) to 4 
(6 on canine teeth) 
 
>0 to 2 (3 on canine 
teeth) 
   2 
Table 2. A summary of the 30 samples used for proteomic discovery. Table shows the unique dog 
identification number, tooth sampled, age at start of study, gender and the week when the 
respective sample was taken. G1 represents very mild gingivitis, G3 moderate gingivitis and PD1 mild 
periodontitis. Teeth are labelled by quadrant (where the first number represents the FDI notation 
for that quadrant) and position in the quadrant (second and third numbers 03 incisor, 04 canine, 07 
premolar, 08 premolar and 09 molar).  
 
Dog ID Tooth 
 
Sex 
 
Age 
(years)  
Sampling week 
G1 
sample 
G3 
sample 
PD1 
sample 
MS05164 207 Male 1.3 6 18 42 
MS05159 409 Female 1.3 0 24 54 
MS04713 104 Male 4.7 0 6 24 
MS04713 304 Male 4.7 0 18 24 
MS04707 408 Female 4.8 0 18 24 
MS04651 208 Female 5.8 0 12 18 
MS05027 103 Male 2.4 0 30 42 
MS05029 209 Female 2.5 0 6 12 
MS05028 108 Male 2.3 18 30 42 
MS05028 209 Male 2.3 0 18 42 
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Table 3.  Results of the univariate mixed model analysis comparing each health state, showing the 41 proteins with significant changes at adjusted p<0.05. 
For each health state comparison, the fold change and 95% confidence intervals are shown along with adjusted p-values. G1 represents very mild gingivitis, 
G3 moderate gingivitis and PD1 mild periodontitis. 
 
Accession UniProt Annotation Putative Group Putative function PD1/G1 
Fold change (CI) & 
Adjusted p-value 
PD1/G3 
Fold change (CI) & 
Adjusted p-value 
G3/G1 
Fold change (CI) & 
Adjusted p-value 
F1PQM1 Purine nucleoside 
phosphorylase 
Biosynthesis Nucleotide synth - Adenosine to A, 
Guanosine to G 
1.59 (1.12, 2.26) 
0.0362 
1.55 (1.09, 2.21) 
0.0438 
1.03 (0.72, 1.46) 
1.0000 
P19006 Haptoglobin Blood 
constituent 
Plasma - binds free haemoglobin, 
inhibits oxidative activity 
2.48 (1.32, 4.66) 
0.0358 
2.42 (1.29, 4.56) 
0.0358 
1.02 (0.54, 1.92) 
1.0000 
E2R0T6 Heat shock 70kDa 
protein 8 
House keeping Multiple including chaperone 
protein & regulator of apoptosis 
1.55 (1.11, 2.16) 
0.0364 
1.48 (1.06, 2.07) 
0.0571 
1.05 (0.75, 1.46) 
1.0000 
E2RAL0 Rho GDP dissociation 
inhibitor (GDI) beta  
House keeping Cell signalling, proliferation, 
cytoskeletal organization, and 
secretion 
1.81 (1.16, 2.83) 
0.0358 
1.87 (1.20, 2.92) 
0.0358 
0.97 (0.62, 1.51) 
1.0000 
F1PBZ4 NAD(P)H:quinone 
oxidoreductase-1 
House keeping Response to oxidative stress 1.68 (1.15, 2.45) 
0.0358 
1.41 (0.96, 2.05) 
0.1732 
1.19 (0.82, 1.74) 
0.7978 
F1PKW7 14-3-3 protein 
beta/alpha 
House keeping Adapter protein 2.00 (1.32, 3.02) 
0.0142 
1.75 (1.16, 2.63) 
0.0358 
1.15 (0.76, 1.73) 
0.9630 
C0LQL0 S100 calcium binding 
protein A8 
Immunity & 
inflammation 
Subunit of Calprotectin - Putative 
inflammatory regulator 
2.28 (1.30, 3.99) 
0.0358 
1.55 (0.89, 2.72) 
0.2866 
1.47 (0.84, 2.57) 
0.4270 
J9P732 S100 calcium binding Immunity & Subunit of Calprotectin - Putative 1.90 (1.17, 3.07) 1.62 (1.00, 2.61) 1.17 (0.73, 1.90) 
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protein A9 inflammation inflammatory regulator 0.0358 0.1124 0.9620 
J9PAQ5 S100 calcium binding 
protein A12 
Immunity & 
inflammation 
Putative anti-inflammatory and cell 
signalling 
2.15 (1.24, 3.71) 
0.0358 
1.84 (1.07, 3.18) 
0.0733 
1.17 (0.67, 2.02) 
1.0000 
E2RCI8 Annexin A6 Immunity & 
inflammation 
Structural or anti-inflammatory 1.81 (1.18, 2.78) 
0.0358 
1.43 (0.93, 2.19) 
0.2420 
1.27 (0.83, 1.95) 
0.6282 
F1P6B7 Annexin A1 Immunity & 
inflammation 
Glucocorticoid anti-inflammatory 1.64 (1.22, 2.21) 
0.0142 
1.36 (1.01, 1.84) 
0.0929 
1.21 (0.89, 1.62) 
0.5154 
F1PIC7 Heat shock protein 5 
(HSPA5) 
Immunity & 
inflammation 
ER overload response 1.74 (1.14, 2.66) 
0.0387 
1.60 (1.05, 2.45) 
0.0738 
1.09 (0.71, 1.66) 
1.0000 
J9NWJ5 Thioredoxin Immunity & 
inflammation 
Redox signalling and oxidative 
stress 
1.64 (1.15, 2.34) 
0.0358 
1.56 (1.10, 2.23) 
0.0438 
1.05 (0.74, 1.50) 
1.0000 
J9P0R6 Myeloperoxidase  Immunity & 
inflammation 
Neutrophil respiratory burst 1.7 (1.16, 2.51) 
0.0358 
1.64 (1.11, 2.42) 
0.0425 
1.04 (0.70, 1.53) 
1.0000 
J9P969 Neuroblast 
differentiation-
associated protein 
AHNAK 
Immunity & 
inflammation 
Interaction with S100 B protein 
1.78 (1.21, 2.62) 
0.0329 
1.57 (1.07, 2.31) 
0.0622 
1.13 (0.77, 1.67) 
0.9657 
P81709 Lysozyme C Immunity & 
inflammation 
Bacterial peptidoglcyan destruction 1.65 (1.16, 2.35) 
0.0358 
1.61 (1.13, 2.29) 
0.0358 
1.03 (0.72, 1.47) 
1.0000 
Q8MJD1 Neutrophil elastase Immunity & 
inflammation 
Neutrophil/ macrophages secreted 1.65 (1.13, 2.40) 
0.0376 
1.59 (1.09, 2.32) 
0.0497 
1.04 (0.71, 1.51) 
1.0000 
E2R2C3 Glucose-6-phosphate 
isomerase 
Metabolic Glycolysis 1.78 (1.36, 2.32) 
0.0005 
1.61 (1.23, 2.11) 
0.0114 
1.10 (0.84, 1.44) 
0.9393 
F1PE09 6-Phosphogluconate Metabolic Pentose phosphate pathway 1.63 (1.14, 2.33) 1.54 (1.08, 2.21) 1.05 (0.74, 1.51) 
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dehydrogenase 0.0358 0.0521 1.0000 
F1PE28 Transketolase  Metabolic Pentose phosphate pathway 1.86 (1.27, 2.71) 
0.0142 
1.63 (1.12, 2.38) 
0.0387 
1.14 (0.78, 1.66) 
0.9525 
H9GW87 Transaldolase Metabolic Links the pentose phosphate 
pathway to glycolysis 
1.67 (1.13, 2.48) 
0.0387 
1.70 (1.15, 2.51) 
0.0358 
0.99 (0.67, 1.46) 
1.0000 
E2QZK2 Uncharacterized 
protein 
NA Uncharacterized putative gelsolin-
like protein 
1.62 (1.10, 2.36) 
0.0438 
1.51 (1.03, 2.21) 
0.0816 
1.07 (0.73, 1.57) 
1.0000 
F1PBL1 Uncharacterized 
protein 
NA Uncharacterized poly(A) RNA 
binding protein 
1.57 (1.09, 2.27) 
0.0447 
1.51 (1.05, 2.17) 
0.0733 
1.04 (0.73, 1.50) 
1.0000 
F1PJ65 Uncharacterized 
protein 
NA Uncharacterized putative GTPase 
protein 
1.47 (1.06, 2.06) 
0.0645 
1.54 (1.10, 2.15) 
0.0410 
0.96 (0.69, 1.34) 
1.0000 
F1PNY2 Uncharacterized 
protein 
NA Uncharacterized protein - Ig-like 
domain 
1.97 (1.30, 2.99) 
0.0142 
1.77 (1.17, 2.68) 
0.0358 
1.11 (0.73, 1.69) 
1.0000 
F1PR54 Uncharacterized 
protein 
NA Uncharacterised transferrin-like 
protein 
1.62 (1.10, 2.39) 
0.0465 
1.60 (1.08, 2.37) 
0.0525 
1.01 (0.68, 1.49) 
1.0000 
J9NYW7 Uncharacterized 
protein 
NA Uncharacterized protein - Ig-like 
domain 
2.38 (1.33, 4.27) 
0.0329 
2.08 (1.16, 3.73) 
0.0438 
1.14 (0.64, 2.05) 
1.0000 
J9P127 Uncharacterized 
protein 
NA Uncharacterized poly(A) RNA 
binding protein 
1.57 (1.02, 2.41) 
0.0927 
1.93 (1.25, 2.97) 
0.0301 
0.81 (0.53, 1.25) 
0.7693 
E2QUU4 Keratin, type II 
cytoskeletal 4 
Structural Cytoskeletal protein 1.86 (1.16, 3.01) 
0.0387 
1.71 (1.06, 2.76) 
0.0733 
1.09 (0.68, 1.76) 
1.0000 
F1PYU9 Keratin, type I 
cytoskeletal 10 
Structural Cytoskeletal protein 1.51 (1.09, 2.10) 
0.0438 
1.25 (0.90, 1.73) 
0.4321 
1.21 (0.87, 1.68) 
0.5839 
E2R4B0 Keratin 78  Structural Cytoskeletal protein 1.87 (1.28, 2.73) 1.62 (1.11, 2.37) 1.15 (0.79, 1.68) 
   6 
0.0142 0.0425 0.9355 
E2R7U2 Keratin 13  Structural Cytoskeletal protein 1.69 (1.20, 2.38) 
0.0301 
1.45 (1.03, 2.05) 
0.0780 
1.16 (0.83, 1.64) 
0.8273 
E2R8Z5 Keratin 5 Structural Cytoskeletal protein 1.57 (1.11, 2.23) 
0.0405 
1.55 (1.09, 2.20) 
0.0438 
1.01 (0.71, 1.44) 
1.0000 
E2RB38 Tropomyosin 1 Structural Actin binding 1.75 (1.17, 2.63) 
0.0358 
1.66 (1.11, 2.49) 
0.0445 
1.06 (0.70, 1.58) 
1.0000 
F1PLS4 Vimentin Structural Type III intermediate filament 1.51 (0.99, 2.31) 
0.1312 
1.78 (1.16, 2.73) 
0.0358 
0.85 (0.55, 1.29) 
0.8977 
H9GWE2 Uridine phosphorylase 
1  
Structural Interacts with vimentin 1.62 (1.13, 2.32) 
0.0358 
1.62 (1.13, 2.33) 
0.0358 
1.00 (0.70, 1.43) 
1.0000 
E2QWN7 Lymphocyte cytosolic 
protein 1  
Structural Actin binding  1.83 (1.18, 2.81) 
0.0358 
1.79 (1.16, 2.76) 
0.0358 
1.02 (0.66, 1.57) 
1.0000 
H9GWB1 Histone H2B Structural DNA packaging 1.69 (1.17, 2.44) 
0.0358 
1.43 (0.99, 2.06) 
0.1262 
1.18 (0.82, 1.70) 
0.8201 
J9P2B7 Histone H2A Structural DNA packaging 1.54 (1.03, 2.31) 
0.0816 
1.67 (1.12, 2.50) 
0.0428 
0.92 (0.62, 1.38) 
1.0000 
L7N0L3 Histone H4  Structural DNA packaging 1.42 (0.97, 2.09) 
0.1644 
1.65 (1.12, 2.42) 
0.0387 
0.86 (0.59, 1.27) 
0.9123 
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Supplemental data 
Supplemental Table 1. All proteins identified from GCF with 2 peptides and in all ten teeth. Table 
shows the listing protein identity (IPI accession number, description and protein identifier), mean 
coverage, mean number of peptides and PSMs (peptide spectrum match) used to identify the protein 
and the estimated abundance (with 95% CI) of the protein identified in each sample type (relative to 
the mastermix). G1 represents very mild gingivitis, G3 moderate gingivitis and PD1 mild 
periodontitis. 
 
Acces
sion  
Description 
Protei
n 
abbrev
iation 
Mean 
covera
ge (%) 
Mean 
number 
of 
peptide
s 
identifi
ed 
Mean 
number 
of PSMs 
G1 (95% 
CI) 
G3 (95% 
CI) 
PD1 
(95% CI) 
A1ILJ
0 
Alpha 1 
antitrypsin  
  12.7 5 32.5 
0.56 
(0.29, 
1.07) 
0.54 
(0.28, 
1.03) 
1.01 
(0.53, 
1.94) 
C0LQ
L0 
S100 calcium 
binding protein 
A8  
S100A
8 
58.5 6.6 49.5 
0.55 
(0.32, 
0.97) 
0.81 
(0.46, 
1.42) 
1.26 
(0.72, 
2.21) 
D6BR
72 
Keratin 71  KRT71 19.7 10.6 68.9 
0.49 
(0.26, 
0.95) 
0.62 
(0.32, 
1.2) 
0.84 
(0.44, 
1.63) 
E2QU
U4 
Uncharacterized 
protein  
KRT71 46.4 35.2 248.1 
0.56 
(0.34, 
0.93) 
0.61 
(0.37, 
1.02) 
1.04 
(0.63, 
1.74) 
E2Q
WN7 
Uncharacterized 
protein  
LCP1 20.9 11.2 65 
0.63 
(0.4, 1) 
0.64 
(0.41, 
1.02) 
1.15 
(0.73, 
1.83) 
E2QZ
K2 
Uncharacterized 
protein  
GSN 11.2 6.7 30.9 
0.7 
(0.45, 
1.07) 
0.75 
(0.48, 
1.15) 
1.12 
(0.73, 
1.73) 
E2QZ
M1 
Uncharacterized 
protein  
YWHA
Q 
25.3 5.9 45.8 
0.75 
(0.51, 
1.11) 
0.74 
(0.5, 1.1) 
1.09 
(0.73, 
1.61) 
E2R0
S6 
Annexin  
ANXA8
L1 
21.7 7.4 41.6 
0.78 
(0.58, 
1.05) 
0.76 
(0.57, 
1.03) 
0.9 
(0.67, 
1.22) 
E2R0
T6 
Uncharacterized 
protein  
HSPA8 20.1 12.3 67.4 
0.7 
(0.48, 
1.01) 
0.73 
(0.51, 
1.06) 
1.09 
(0.75, 
1.57) 
E2R2
C3 
Gluce-6-phphate 
isomerase  
GPI 12 5.2 28.3 
0.64 
(0.46, 
0.89) 
0.7 (0.5, 
0.98) 
1.13 
(0.81, 
1.58) 
E2R4 Uncharacterized CAPG 17.8 5.6 33.6 0.75 0.65 1 (0.71, 
13 protein  (0.53, 
1.06) 
(0.46, 
0.92) 
1.4) 
E2R4
B0 
Uncharacterized 
protein  
KRT78 14.3 7.7 55.7 
0.59 
(0.37, 
0.94) 
0.68 
(0.43, 
1.09) 
1.11 
(0.7, 
1.76) 
E2R5
P5 
Uncharacterized 
protein  
S100A
6 
26.7 3.2 14.7 
0.84 
(0.61, 
1.16) 
0.76 
(0.55, 
1.05) 
1.05 
(0.76, 
1.44) 
E2R5
W6 
Uncharacterized 
protein  
GC 16.2 6.7 43.7 
0.58 
(0.35, 
0.98) 
0.56 
(0.34, 
0.95) 
0.97 
(0.57, 
1.63) 
E2R6
62 
Uncharacterized 
protein  
TPM4 18.9 6.9 35.1 
0.64 
(0.42, 
0.96) 
0.66 
(0.44, 
1.01) 
1.03 
(0.68, 
1.57) 
E2R7
A4 
Involucrin  IVL 34.9 8.6 53.4 
0.76 
(0.56, 
1.05) 
0.78 
(0.57, 
1.08) 
0.96 
(0.7, 
1.32) 
E2R7
U2 
Uncharacterized 
protein  
KRT13 54 29.4 246.2 
0.63 
(0.42, 
0.94) 
0.73 
(0.49, 
1.09) 
1.06 
(0.71, 
1.58) 
E2R8
Q7 
Uncharacterized 
protein  
KRT15 35.1 19.9 137.4 
0.74 
(0.5, 
1.11) 
0.73 
(0.49, 
1.08) 
1.19 
(0.8, 
1.78) 
E2R8
Z5 
Uncharacterized 
protein  
KRT5 48.5 37.1 299.6 
0.65 
(0.45, 
0.95) 
0.66 
(0.45, 
0.96) 
1.02 
(0.71, 
1.49) 
E2RA
L0 
Uncharacterized 
protein  
ARHG
DIB 
27.2 3.9 23.3 
0.62 
(0.39, 1) 
0.6 
(0.38, 
0.97) 
1.13 
(0.7, 
1.81) 
E2RB
38 
Uncharacterized 
protein  
TPM1 22.6 7.3 36 
0.66 
(0.43, 
1.02) 
0.7 
(0.45, 
1.08) 
1.16 
(0.75, 
1.79) 
E2RCI
8 
Annexin 
(Fragment)  
ANXA6 11.1 6.2 27.6 
0.61 
(0.41, 
0.91) 
0.78 
(0.52, 
1.16) 
1.11 
(0.75, 
1.65) 
E2RH
G2 
Uncharacterized 
protein  
PRDX1 31.8 7.4 48.8 
0.72 
(0.51, 
1.02) 
0.81 
(0.58, 
1.15) 
1 (0.71, 
1.41) 
E2RL
S3 
Uncharacterized 
protein  
SLC29
A1 
15.2 10.9 63.5 
0.74 
(0.53, 
1.04) 
0.72 
(0.51, 
1.01) 
1.1 
(0.78, 
1.56) 
E2RR
C9 
Phphoglycerate 
kinase  
PGK1 15.3 6.3 24.9 
0.75 
(0.53, 
1.07) 
0.7 
(0.49, 1) 
1.07 
(0.75, 
1.52) 
E2RSI
6 
Uncharacterized 
protein  
EZR 25.5 17.5 96.9 
0.71 
(0.5, 1) 
0.78 
(0.55, 
1.1) 
1.04 
(0.73, 
1.48) 
F1P6
B7 
Uncharacterized 
protein  
ANXA1 41.8 14.4 119.3 
0.65 
(0.48, 
0.88) 
0.79 
(0.58, 
1.06) 
1.07 
(0.79, 
1.45) 
F1PB
L1 
Uncharacterized 
protein  
YWHA
Z 
45.7 9.7 71.3 
0.73 
(0.52, 
1.04) 
0.76 
(0.54, 
1.08) 
1.15 
(0.81, 
1.63) 
F1PB
Z4 
Uncharacterized 
protein 
(Fragment)  
NQO1 21.6 6.7 58.1 
0.66 
(0.46, 
0.96) 
0.79 
(0.55, 
1.15) 
1.12 
(0.77, 
1.62) 
F1PC
G4 
Uncharacterized 
protein  
PRDX2 18.5 3 18.7 
0.46 
(0.24, 
0.88) 
0.68 
(0.35, 
1.3) 
0.72 
(0.37, 
1.39) 
F1PC
H3 
Enolase  ENO1 33.6 11.9 107.5 
0.77 
(0.55, 
1.09) 
0.74 
(0.52, 
1.05) 
0.98 
(0.7, 
1.39) 
F1PC
K2 
Uncharacterized 
protein  
A1BG 6.3 3.3 15.7 
0.59 
(0.34, 
1.02) 
0.51 
(0.29, 
0.88) 
0.93 
(0.54, 
1.61) 
F1PD
J5 
Apolipoprotein A-I  APOA1 77.5 29.7 373.9 
0.44 
(0.23, 
0.83) 
0.45 
(0.24, 
0.85) 
0.8 
(0.43, 
1.51) 
F1PE
09 
6-phphogluconate 
dehydrogenase, 
decarboxylating  
PGD 21.5 10.2 62.6 
0.69 
(0.49, 
0.99) 
0.73 
(0.51, 
1.04) 
1.13 
(0.79, 
1.61) 
F1PE
28 
Uncharacterized 
protein  
TKT 31.6 15.8 72.7 
0.65 
(0.42, 
0.99) 
0.74 
(0.48, 
1.13) 
1.21 
(0.79, 
1.84) 
F1PG
S2 
Fibrinogen beta 
chain (Fragment)  
FGB 9.7 4 15.6 
0.47 
(0.26, 
0.86) 
0.52 
(0.28, 
0.94) 
0.99 
(0.54, 
1.81) 
F1PG
Y1 
Uncharacterized 
protein 
(Fragment)  
HSP90
AA1 
15.1 9 54.5 
0.67 
(0.46, 1) 
0.74 
(0.5, 1.1) 
1.08 
(0.73, 
1.6) 
F1PH
R2 
Pyruvate kinase  PKM 26.9 12.5 84.9 
0.67 
(0.48, 
0.92) 
0.7 
(0.51, 
0.97) 
1.05 
(0.76, 
1.45) 
F1PIC
7 
Uncharacterized 
protein  
HSPA5 8.9 4.8 26.1 
0.65 
(0.41, 
1.02) 
0.7 
(0.45, 
1.11) 
1.13 
(0.71, 
1.78) 
F1PJ6
5 
Uncharacterized 
protein  
IQGAP
1 
4.7 5.1 23.5 
0.76 
(0.55, 
1.05) 
0.73 
(0.53, 
1.01) 
1.12 
(0.81, 
1.55) 
F1PK
W7 
Uncharacterized 
protein  
YWHA
B 
25.7 5.9 44.8 
0.61 
(0.4, 
0.93) 
0.7 
(0.46, 
1.06) 
1.22 
(0.81, 
1.85) 
F1PL
93 
Uncharacterized 
protein  
ARHG
DIA 
19.1 3.3 20.3 
0.72 
(0.5, 
1.04) 
0.69 
(0.48, 
0.99) 
1.06 
(0.74, 
1.53) 
F1PLS
4 
Uncharacterized 
protein  
VIM 17.1 9 43 
0.74 
(0.48, 
1.13) 
0.62 
(0.41, 
0.95) 
1.11 
(0.73, 
1.7) 
F1PN
Y2 
Uncharacterized 
protein  
  8.8 2 9.9 
0.54 
(0.32, 
0.6 
(0.35, 
1.07 
(0.62, 
0.93) 1.03) 1.83) 
F1PQ
93 
Uncharacterized 
protein  
SFN 47.6 10.5 72.5 
0.77 
(0.55, 
1.06) 
0.73 
(0.53, 
1.01) 
0.97 
(0.7, 
1.34) 
F1PQ
M1 
Purine nucleide 
phphorylase  
PNP 25 6.2 41 
0.73 
(0.52, 
1.02) 
0.74 
(0.53, 
1.04) 
1.16 
(0.82, 
1.62) 
F1PQ
N5 
Uncharacterized 
protein 
(Fragment)  
CFL1 33.9 4.9 26.4 
0.79 
(0.55, 
1.14) 
0.69 
(0.48, 1) 
1.07 
(0.74, 
1.54) 
F1PR
54 
Uncharacterized 
protein  
LTF 17.8 11.6 61.1 
0.67 
(0.45, 1) 
0.68 
(0.45, 
1.01) 
1.09 
(0.73, 
1.62) 
F1PS
X2 
Uncharacterized 
protein 
(Fragment)  
  50.3 3.6 52.6 
0.52 
(0.28, 
0.95) 
0.63 
(0.35, 
1.16) 
0.98 
(0.54, 
1.79) 
F1PT
S8 
Uncharacterized 
protein 
(Fragment)  
KRT6A 43 29.8 224.9 
0.75 
(0.51, 
1.1) 
0.79 
(0.54, 
1.16) 
0.98 
(0.67, 
1.45) 
F1PV
W0 
L-lactate 
dehydrogenase  
LDHA 31.7 10.5 63.4 
0.78 
(0.56, 
1.1) 
0.77 
(0.55, 
1.08) 
1.13 
(0.8, 
1.59) 
F1PY
E3 
Heat shock 
protein beta-1  
HSPB1 34.4 8.1 62 
0.75 
(0.54, 
1.04) 
0.76 
(0.55, 
1.06) 
0.87 
(0.62, 
1.21) 
F1PY
U9 
Keratin, type I 
cytkeletal 10  
KRT10 26.5 16.1 103.8 
0.67 
(0.44, 
1.03) 
0.81 
(0.53, 
1.25) 
1.01 
(0.66, 
1.56) 
F1PZ
R4 
Uncharacterized 
protein  
HPX 10.6 4.1 25.5 
0.41 
(0.23, 
0.75) 
0.41 
(0.23, 
0.75) 
0.81 
(0.44, 
1.46) 
F1Q0
R0 
Uncharacterized 
protein  
KRT16 36.9 20.3 156.3 
0.67 
(0.46, 
0.99) 
0.66 
(0.45, 
0.97) 
0.98 
(0.67, 
1.44) 
F1Q3
U2 
Uncharacterized 
protein  
KRT76 28.8 24.1 143.4 
0.55 
(0.32, 
0.96) 
0.55 
(0.31, 
0.96) 
1.03 
(0.59, 
1.79) 
G1K2
67 
Uncharacterized 
protein  
  9.9 5.9 29.1 
0.66 
(0.46, 
0.96) 
0.67 
(0.46, 
0.97) 
0.89 
(0.62, 
1.3) 
H9G
W87 
Transaldolase  
TALDO
1 
19 7.7 33.4 
0.7 
(0.48, 
1.02) 
0.69 
(0.47, 
1.01) 
1.17 
(0.8, 
1.71) 
H9G
WB1 
Histone H2B  
LOC47
8743 
38.1 5.7 53.1 
0.64 
(0.4, 
1.03) 
0.76 
(0.47, 
1.22) 
1.09 
(0.68, 
1.74) 
H9G
WE2 
Uncharacterized 
protein  
UPP1 11.5 2.9 15.7 
0.68 
(0.47, 
0.99) 
0.68 
(0.47, 
0.99) 
1.11 
(0.76, 
1.6) 
J9NW Thioredoxin TXN 25.7 3.2 16.9 0.68 0.72 1.12 
J5 (Fragment)  (0.46, 1) (0.49, 
1.05) 
(0.76, 
1.64) 
J9NY
W7 
Uncharacterized 
protein 
(Fragment)  
  13.3 5.9 69.8 
0.44 
(0.24, 
0.79) 
0.5 
(0.28, 
0.91) 
1.05 
(0.58, 
1.89) 
J9P0R
6 
Uncharacterized 
protein  
MPO 14.5 9.8 64.2 
0.65 
(0.43, 1) 
0.68 
(0.45, 
1.03) 
1.12 
(0.73, 
1.7) 
J9P12
7 
Uncharacterized 
protein  
LOC10
06833
70 
55.2 5.3 29.7 
0.7 
(0.46, 
1.07) 
0.57 
(0.37, 
0.87) 
1.09 
(0.71, 
1.68) 
J9P2B
7 
Histone H2A  
LOC48
8299 
31 4 35.5 
0.72 
(0.48, 
1.1) 
0.67 
(0.44, 
1.01) 
1.12 
(0.74, 
1.69) 
J9P4Y
2 
Uncharacterized 
protein  
S100A
2 
32.6 5.2 39.5 
0.7 
(0.51, 
0.97) 
0.87 
(0.63, 
1.19) 
1.09 
(0.79, 
1.49) 
J9P73
2 
Uncharacterized 
protein 
(Fragment)  
S100A
9 
25 8.3 43.9 
0.65 
(0.42, 1) 
0.76 
(0.49, 
1.18) 
1.23 
(0.79, 
1.91) 
J9P96
9 
Uncharacterized 
protein  
AHNA
K 
15.8 12.7 66.6 
0.62 
(0.41, 
0.94) 
0.7 
(0.46, 
1.07) 
1.1 
(0.72, 
1.67) 
J9P9J
6 
Uncharacterized 
protein  
  12.8 4.5 36.1 
0.35 
(0.19, 
0.67) 
0.44 
(0.23, 
0.84) 
0.63 
(0.33, 
1.19) 
J9PA
Q5 
Uncharacterized 
protein  
S100A
12 
64 10 101.6 
0.54 
(0.3, 
0.95) 
0.62 
(0.35, 
1.1) 
1.15 
(0.65, 
2.03) 
J9PB
N6 
Uncharacterized 
protein  
LOC61
1458 
6.4 9.5 37.4 
0.44 
(0.24, 
0.79) 
0.43 
(0.24, 
0.78) 
0.86 
(0.47, 
1.55) 
L7N0
94 
Uncharacterized 
protein  
KRT3 23.6 21.4 172 
0.64 
(0.4, 
1.04) 
0.7 
(0.43, 
1.12) 
1.08 
(0.67, 
1.74) 
L7N0
95 
Uncharacterized 
protein 
(Fragment)  
KRT5 45.4 30.6 236.7 
0.65 
(0.44, 
0.98) 
0.68 
(0.45, 
1.02) 
0.98 
(0.65, 
1.48) 
L7N0
F2 
Uncharacterized 
protein  
LOC48
6474 
42.3 3.6 50.7 
0.45 
(0.24, 
0.84) 
0.51 
(0.27, 
0.97) 
0.87 
(0.46, 
1.63) 
L7N0
L3 
Histone H4 
(Fragment)  
LOC61
1192 
58.3 7.7 77.3 
0.74 
(0.48, 
1.15) 
0.64 
(0.41, 1) 
1.05 
(0.68, 
1.64) 
P051
24 
Creatine kinase B-
type  
CKB 15.4 4.5 29 
0.79 
(0.54, 
1.15) 
0.78 
(0.54, 
1.14) 
0.93 
(0.64, 
1.35) 
P190
06 
Haptoglobin  HP 29.3 9.9 66.4 
0.37 
(0.21, 
0.66) 
0.38 
(0.21, 
0.67) 
0.91 
(0.51, 
1.62) 
P498
22 
Serum albumin  ALB 62.6 45.4 536.3 
0.62 
(0.32, 
1.2) 
0.64 
(0.33, 
1.25) 
0.88 
(0.45, 
1.72) 
P547
14 
Triephphate 
isomerase  
TPI1 31.1 6.3 30.9 
0.72 
(0.52, 
1.01) 
0.71 
(0.51, 
0.99) 
1.04 
(0.74, 
1.46) 
P605
24 
Hemoglobin 
subunit beta  
HBB 86.3 16.4 322.7 
0.18 
(0.06, 
0.51) 
0.24 
(0.09, 
0.68) 
0.39 
(0.14, 
1.1) 
P817
09 
Lysozyme C, 
spleen isozyme  
  34.3 4.9 25.2 
0.58 
(0.37, 
0.92) 
0.6 
(0.38, 
0.95) 
0.96 
(0.61, 
1.53) 
Q6TE
Q7 
Annexin A2  ANXA2 41.2 16.1 106.5 
0.76 
(0.54, 
1.07) 
0.77 
(0.55, 
1.09) 
1.07 
(0.77, 
1.51) 
Q8MJ
D1 
Neutrophil 
elastase  
ELA2 12.6 3.4 14.4 
0.69 
(0.46, 
1.02) 
0.71 
(0.48, 
1.06) 
1.13 
(0.76, 
1.68) 
Q9M
ZD3 
Peptidyl-prolyl cis-
trans isomerase 
(Fragment)  
  29.3 5.7 40.1 
0.61 
(0.33, 
1.11) 
0.55 
(0.3, 
1.01) 
1 (0.55, 
1.83) 
Supplemental Table 2. Data from ELISAs for haptoglobin, S100A8, myosin 9, keratin type 1 
cytoskeletal 10, pyruvate kinase and anti-immunoglobulin binding protein (IBPAb). Those marked in 
red are below lower limit of detection. G1 represents very mild gingivitis and PD1 mild periodontitis. 
Dog Name Dog ID Tooth 
Haptoglobin (ng/ml) 
G1 State PD1 State 
Dickens MS04594 108 11.45 33.01 
Dallas MS04595 208 31.68 116.46 
Winston MS04648 408 >131.15 >131.15 
Emerald MS04650 108 89.63 86.90 
Nettie MS04923 208 81.52 121.03 
Eddie MS04714 208 42.89 102.00 
Edna MS04715 308 98.04 64.93 
Whoopee MS05108 308 3.70 85.47 
Bramble MS05151 109 41.94 41.94 
Yoshi MS05118 308 41.92 78.38 
 
 
Dog Name Dog ID Tooth 
S100A8 (pg/ml) 
G1 State PD1 State 
Dallas MS04595 209 848.50 162.17 
Edna MS04715 309 350.55 197.55 
Jigsaw MS04846 209 149.47 228.30 
Nettie MS04923 409 101.26 354.26 
Noodle MS04924 408 112.21 151.05 
Vinnie MS05028 409 174.11 324.80 
Valerie MS05030 308 104.51 660.86 
Whoopee MS05108 309 191.41 623.69 
Winston MS04648 109 463.30 325.65 
Oxo MS04935 308 431.53 206.58 
  
Dog Name Dog ID Tooth 
Myosin 9 (pg/ml) 
G1State PD1 State 
Dallas MS04595 308 19.68 32.30 
Rooney MS04599 408 25.49 32.68 
Mimi MS04645 309 22.90 24.92 
Winston MS04648 208 32.58 33.84 
Eddie MS04714 207 27.67 32.43 
Emerald MS04650 308 33.50 30.59 
Jigsaw MS04846 308 40.43 24.93 
Ethel MS04707 308 34.80 30.17 
Nettie MS04923 309 17.98 29.88 
Custard MS05159 209 50.50 30.12 
    
Dog Name Dog ID Tooth 
Keratin type 1 cytoskeletal 10   
(ng/ml) 
G1State PD1 State 
Winston MS04648 308 0.83 0.57 
China MS04563 109 0.11 0.63 
Bramble MS05151 409 0.43 0.32 
Mimi MS04645 308 0.19 0.36 
Arnie MS04561 408 <0 0.16 
Colin MS05164 104 0.18 0.41 
Chesney MS05163 408 <0 0.46 
Brock MS05156 208 0.41 0.73 
Bentley MS05152 309 0.46 0.41 
Wanda MS05113 204 0.45 0.45 
     
 
     
Dog Name Dog ID Tooth 
Pyruvate Kinase  (ng/ml) 
G1State PD1 State 
Nettie MS04923 308 0.55 0.48 
Vinnie MS05028 309 0.03 0.25 
Violet MS05031 309 0.35 0.50 
Whoopee MS05108 409 0.76 0.17 
Wotsit MS05112 308 0.21 0.45 
Bramble MS05151 308 0.07 0.15 
Yetti MS05120 209 1.15 0.41 
Yoda MS05119 309 0.41 1.07 
Yasmine MS05114 408 0.44 0.40 
Yoshi MS05118 309 0.40 0.57 
 
     
Dog Name Dog ID Tooth 
IBPAb (ug/ml) 
G1State PD1 State 
Edna MS04715 409 <0.07812 <0.07812 
Jigsaw MS04846 409 <0.07813 <0.07812 
Nettie MS04923 209 0.1911 <0.07812 
Noodle MS04924 409 <0.07813 <0.07812 
Niamh MS04930 308 0.3394 <0.07812 
Oxo MS04935 408 0.2404 <0.07812 
Usher MS05024 209 0.3755 <0.07812 
Vinnie MS05028 208 <0.07812 <0.07812 
Valerie MS05030 408 <0.07812 <0.07812 
Bramble MS05151 204 <0.07812 <0.07812 
 
 
